Focal HDR-Brachytherapy for Prostate Cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study uses focal high-dose-rate brachytherapy to treat the dominant lesion in men with early- to intermediate-stage prostate cancer. Participants may receive up to two HDR-BT treatments spaced at least three weeks apart, with imaging, biopsy, and biospecimen collection throughout. Follow-up includes regular PSA testing, imaging, and quality-of-life assessments to monitor disease control and treatment-related toxicity. The trial aims to measure local control and urinary/ GI toxicity, as well as progression-free survival, distant metastasis-free survival, overall survival, and changes in quality of life.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Histologically confirmed diagnosis of prostate adenocarcinoma within 90 days prior to registration via systematic biopsy
* Multiparametric MRI (mp-MRI) confirmed lesion(s)
* No distant or locally advanced disease on standard staging exams as indicated

  * Bone scan and abdominopelvic computed tomography (CT)/MRI OR
  * PSMA PET
* Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status 0/1 within 60 days prior to enrollment
* Age ≥ 40

Exclusion Criteria:

* Radiographic nodal or distant metastatic disease
* Lesion(s) comprising \> 40% of total prostate volume
* Prior radiotherapy to the pelvis
* Gleason score \> 6 disease outside intended gross target volume (GTV)/target region(s)

Where it's running

• UCLA / Jonsson Comprehensive Cancer Center
  Los Angeles, California, United States Recruiting

Study contacts

• Principal investigator: Alan C Lee — UCLA / Jonsson Comprehensive Cancer Center

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Golf exercise program for prostate cancer survivors

  This study tests whether a 10-week golf exercise program can help prostate cancer survivors feel better physically and mentally.

  Recruiting at 2 sites University of Southern California · Los Angeles, California and 1 other locations · NCT06500169

• Hormone therapy and targeted radiation for prostate cancer treatment

  This study is testing if combining a hormone therapy that blocks testosterone with targeted radiation can help men with prostate cancer see better results and improve their quality of life.

  Recruiting Phase 2 Jonsson Comprehensive Cancer Center · Los Angeles, California · NCT06067269

• MRI or CT planning to guide high-dose-rate prostate brachytherapy

  This trial tests whether adding an MRI to CT-based treatment planning for HDR prostate brachytherapy changes urinary side effects in men with localized prostate cancer.

  Recruiting at 3 sites Emory University · Atlanta, Georgia and 2 other locations · NCT07859722

• Exercise after pelvic radiation to see if it lowers colorectal cancer risk

  This study tests whether regular walking therapy after pelvic radiation for prostate cancer can influence markers of colorectal cancer in colon tissue and blood.

  Recruiting at 2 sites City of Hope Medical Center · Duarte, California and 1 other locations · NCT07790718

• PSMA-targeted therapy with hormone suppression for low-volume metastatic prostate cancer

  This phase II trial tests leuprolide acetate alone versus with 177Lu-PSMA-617 (with or without abiraterone acetate and prednisone) in men with hormone-sensitive, low-volume metastatic prostate cancer.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT07650240

• Lower-dose radiation to parts of the prostate for some men with prostate cancer

  This study tests whether a smaller amount of radiation aimed at specific parts of the prostate can reduce side effects compared with giving the full prostate the same dose.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07635238

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.